Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion

Taylor and Francis Group, Expert Review of Anticancer Therapy, 12(22), p. 1265-1274, 2022

Journal article published in 2022 by Michael H. Storandt, Zhaohui Jin

, Amit Mahipal

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by